Compass Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

CMPX$0.84+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

Condensed Consolidated Balance Sheets

(In thousands, except par value)

	September 30, 2026 (unaudited)	December 31, 2025 (Note 1)
Assets
Current assets:
Cash and cash equivalents	$41,469	$30,643
Marketable securities	121,589	178,263
Prepaid expenses and other current assets	2,439	913
Total current assets	165,497	209,819
Property and equipment, net	402	102
Operating lease, right-of-use ("ROU") asset	8,031	9,099
Restricted cash	568	568
Total assets	$174,498	$219,588
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$6,316	$1,585
Accrued expenses	16,378	11,383
Operating lease obligations, current portion	1,674	1,000
Total current liabilities	24,368	13,968
Operating lease obligations, long-term portion	7,560	8,829
Total liabilities	31,928	22,797
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 180,088 and 178,324 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	18	18
Additional paid-in-capital	644,932	627,665
Accumulated other comprehensive income (loss)	(566)	280
Accumulated deficit	(501,814)	(431,172)
Total stockholders' equity	142,570	196,791
Total liabilities and stockholders' equity	$174,498	$219,588

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.